Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The emerging role of human transmembrane RGD-based counter-receptors of integrins in health and disease

  • Cabañas, Carlos
  • Rossi, Elisa
  • Bartolomé, Rubén Álvaro
  • Doberstein, Kai
  • Altevogt, Peter
  • Casal, J. Ignacio
  • Bernabéu, Carmelo
Most of the canonical Arg-Gly-Asp (RGD)-containing integrin ligands are extracellular matrix proteins, such as fibronectin, vitronectin and fibrinogen, which regulate cell-ECM adhesion processes. However, during the last years, several reports have demonstrated the existence of non-canonical RGD-containing integrin ligands that are cell surface transmembrane proteins. At variance with the canonical extracellular matrix integrin ligands, the RGD-containing cell surface integrin ligands are involved in cell-cell adhesion processes and function as "integrin counter-receptors". We propose in this review grouping these transmembrane proteins, which include endoglin, cadherin-5, cadherin-6, cadherin-17, ADAM15, and L1CAM, under the newly coined acronym RGD-ICRs (RGD-containing Integrin Counter-Receptors). We present and discuss the structure of RGD-ICRs, their RGD-based interactions with integrins, the specific signaling pathways triggered in different cell types, as well as their pathophysiological involvement. It can be postulated that RGD-ICRs constitute an emerging group of non-canonical RGD-based integrin counter-receptors. In spite of being encoded by different and independent genes and involved in different pathophysiological processes, all of them appear to have undergone a strong evolutionary convergence in order to acquire the same functional capacity to bind integrins via the RGD motif. Importantly, these RGD-ICRs are also emerging as novel biomarkers and therapeutic targets, with promising clinical potential in a wide array of pathologies., C.C. was supported by grant no. PID2021-123199OB-I00 of the Ministerio de Ciencia e Innovaci\u00F3n (Spain) (MCIN/AEI/https://doi.org/10.13039/501100011033) and by the European Union. The CBM-SO is a \u201CSevero Ochoa Center of Excellence\u201D (grant no. CEX2021-001154-S) funded by MICIN/AEI/https://doi.org/10.13039/501100011033 and receives an institutional grant from the Fundaci\u00F3n Ram\u00F3n Areces. J.I.C. was supported by grant nos. PID2021-122227OB-I00 of the Ministerio de Ciencia e Innovaci\u00F3n (Spain) and PMPTA22/00108 from the Instituto de Salud Carlos III using Next Generation EU/PRTR funds from the MCIN/AEI/https://doi.org/10.13039/501100011033. C.B. was supported by the Consejo Superior de Investigaciones Cient\u00EDficas (CSIC, Spain) (grant no. 201920E022)., Peer reviewed